BMC has introduced three new fully open access journals—Immuno‑Oncology, Journal of Fibrosis, and Translational and Clinical Neuroinflammation—to support the translation of research into clinical practice. The journals are intended to provide dedicated platforms for fast‑moving research communities and form part of Springer Nature’s open access portfolio, which now includes more than 770 journals across six brands.
Selene Carey, Publishing Director at BMC, stated that many of the most significant advances in medicine depend on collaboration between researchers and clinicians. She explained that the new journals are designed to give each community a dedicated venue to connect scientific discoveries with clinical practice, ensuring that research reaches those who can build upon it.
All articles published in the journals will be freely available worldwide, supporting visibility and impact for authors and readers. Springer Nature has reported that publications in its full open access journals achieve high usage and an average of 7.6 citations per article, according to its latest Open Access Report.
The scope of the new journals includes:
• Immuno‑Oncology, focusing on the interface between immunology and cancer research, where laboratory findings can inform improved understanding and treatment of cancer.
• Journal of Fibrosis, bringing together research across organ systems and disciplines to advance knowledge, diagnosis, and treatment of fibrotic diseases.
• Translational and Clinical Neuroinflammation, connecting research across the discovery‑to‑clinic continuum to advance understanding of neuroinflammatory diseases and support new treatment approaches.
These journals join Sustainability, Uterine Research, and Psychedelic Substances Research, which were launched earlier in 2026, building on BMC’s more than 25 years of open access publishing in medicine and the life sciences.
Click here to read the original press release.
